Company Overview and News
OTTAWA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV-ORE) announces that it has filed an independent National Instrument (“NI”) 43-101 technical report entitled "Feasibility Study of the Bomboré Gold Project, Burkina Faso” with an effective date of July 9, 2018. The feasibility results were previously announced by the Company in a news release dated July 9, 2018.
OTTAWA, July 31, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV:ORE) (“Orezone” or the “Company”) is pleased to report ongoing results from its targeted shallow infill Reverse Circulation Drilling (“RC”) and Diamond Core Drilling (“DD”) within the Bomboré mining lease. This programme totalled 196 RC boreholes (12,193 m) and 30 DD boreholes (3,756 m) that were drilled during Q2 2018 in the Maga, P11 and Siga East areas.
OTTAWA, July 16, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV:ORE) (“Orezone” or the “Company”) is pleased to report recent Reverse Circulation (“RC”) and Diamond Drilling (“DD”) drilling results from several target areas that lie outside of the main Bomboré deposit mining permit. This programme totalled 55 RC boreholes (2,904 m) and 34 DD boreholes (4,916.5 m) that were drilled during Q1 2018.
Orezone just released an Updated Feasibility Study highlighting their Bomboré project as possessing: strong economics, modest CapEx, quick payback, simple mine plan, and ample remaining development/exploration upside potential.
ORZCF WFRSF BTG WAF EDVVF EDVMF EVR OCR EDV ORE
OTTAWA, July 09, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSXV:ORE) (“Orezone” or the “Company”) is pleased to announce the summary results of an updated independent Feasibility Study (the “FS”) for its 90%-owned Bomboré Gold Project in Burkina Faso, West Africa. All reported figures are in U.S. dollars and are on a 100% project basis unless otherwise stated.
ORZCF MALRY MALRF MIN ORE
OTTAWA, April 10, 2018 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX-V:ORE) (“Orezone” or the “Company”) is pleased to announce that it has closed its non-brokered private placement (the “Offering”) previously-announced on March 26, 2018. The Company has sold 56,150,000 common shares of the Company (“Common Shares”) at a price of C$0.80 per share for gross proceeds of C$44,920,000. The Common Shares issued pursuant to the Offering will be subject to a four month hold period expiring on August 10, 2018.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:ORE / Orezone Gold Corporation on message board site Silicon Investor.